Provided by Tiger Trade Technology Pte. Ltd.

QYUNS-B

16.420
+0.0800.49%
Volume:24.60K
Turnover:401.67K
Market Cap:3.66B
PE:9.97
High:16.840
Open:16.480
Low:16.050
Close:16.340
52wk High:36.500
52wk Low:13.210
Shares:223.00M
HK Float Shares:223.00M
Volume Ratio:0.55
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.647
ROE:101.58%
ROA:22.80%
PB:3.64
PE(LYR):9.97
PS:3.06

Loading ...

QYUNS-B (02509) Repurchases 174,400 Shares for Approximately HK$2.81 Million on June 1

Stock News
·
Jun 01

Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares

Bulletin Express
·
Jun 01

Qyuns Therapeutics Updates Articles of Association: Clarifies Share Structure, Governance Framework and Dividend Policy

Bulletin Express
·
May 29

Qyuns Therapeutics dissolves supervisory committee as supervisors resign

Reuters
·
May 29

Qyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units

Bulletin Express
·
May 28

BRIEF-Qyuns Therapeutics Co Receives Milestone Payment From Roche

Reuters
·
May 27

QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N

Stock News
·
May 27

Qyuns Therapeutics receives Roche milestone payment after first QX031N Phase I patient dosed

Reuters
·
May 27

Qyuns Therapeutics Co - Receives Milestone Payment From Roche for First Participant Dosed in Phase I QX031n Trial

THOMSON REUTERS
·
May 27

QYUNS-B (02509) Allocates HK$2.19 Million for Share Buyback on May 27

Stock News
·
May 27

Qyuns Therapeutics files HKEX next-day return disclosing share repurchase at HKD 16.31 each

Reuters
·
May 27

Qyuns Therapeutics secures NMPA approval for biosimilar QX001S (Ustekinumab) in Crohn’s disease, in partnership with Zhongmei Huadong

Bulletin Express
·
May 21

QYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease

Stock News
·
May 21

Qyuns Therapeutics - Zhongmei Huadong Receives Approvals for QX001s (Ustekinumab Injection) for Crohn's Disease

THOMSON REUTERS
·
May 21

QYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study

Stock News
·
May 11

Qyuns Therapeutics Rolls Out 10-Year Share Incentive Plan; Mandate Capped at 10% of Issued H Shares

Bulletin Express
·
May 08

Qyuns Therapeutics to Vote on Profit Distribution, KPMG Re-appointment and New 2026 Share Incentive Scheme at 29 May 2026 AGM

Bulletin Express
·
May 08

Qyuns Therapeutics Tables Key AGM Proposals: No 2025 Dividend, HK$111.70 Million Proceeds Reallocated, Launches 10-Year Share Incentive Scheme

Bulletin Express
·
May 08

Qyuns Therapeutics announces annual general meeting

Reuters
·
May 08

BRIEF-Qyuns Therapeutics To Subscribe PDB Wealth Product With RMB100 Million Principal

Reuters
·
Apr 29